Correlation Between CytomX Therapeutics and Vor Biopharma

Can any of the company-specific risk be diversified away by investing in both CytomX Therapeutics and Vor Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining CytomX Therapeutics and Vor Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between CytomX Therapeutics and Vor Biopharma, you can compare the effects of market volatilities on CytomX Therapeutics and Vor Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in CytomX Therapeutics with a short position of Vor Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of CytomX Therapeutics and Vor Biopharma.

Diversification Opportunities for CytomX Therapeutics and Vor Biopharma

0.04

Correlation Coefficient

CytomX Therapeutics  Vor Biopharma

Significant diversification

The 3 months correlation between CytomX and Vor is 0.04. Overlapping area represents the amount of risk that can be diversified away by holding CytomX Therapeutics and Vor Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vor Biopharma and CytomX Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on CytomX Therapeutics are associated (or correlated) with Vor Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vor Biopharma has no effect on the direction of CytomX Therapeutics i.e., CytomX Therapeutics and Vor Biopharma go up and down completely randomly.

Pair Corralation between CytomX Therapeutics and Vor Biopharma

Given the investment horizon of 90 days CytomX Therapeutics is expected to under-perform the Vor Biopharma. But the stock apears to be less risky and, when comparing its historical volatility, CytomX Therapeutics is 1.39 times less risky than Vor Biopharma. The stock trades about -0.02 of its potential returns per unit of risk. The Vor Biopharma is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  90.00  in Vor Biopharma on September 20, 2024 and sell it today you would lose (1.00) from holding Vor Biopharma or give up 1.11% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

CytomX Therapeutics  vs.  Vor Biopharma

CytomX Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days CytomX Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's primary indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Vor Biopharma

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Vor Biopharma are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively conflicting basic indicators, Vor Biopharma may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with CytomX Therapeutics and Vor Biopharma

The main advantage of trading using opposite CytomX Therapeutics and Vor Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if CytomX Therapeutics position performs unexpectedly, Vor Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vor Biopharma will offset losses from the drop in Vor Biopharma's long position.

The idea behind CytomX Therapeutics and Vor Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.